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Use of B-lymphocyte (CD19D) Count as a Guide to Adjust the Doses of
Rituximab Infusion in Paediatric Patients
Wun Fung Hui
Queen Elizabeth Hospital, Hong Kong
Introduction: Rituximab is a chimeric murine /human monoclonal antibody
which has emerged as a novel therapy for various glomerular diseases in
Children. The optimal doses remain uncertain. We presented our experience
by monitoring the B-lymphocyte (CD19+) subset count as a guide to adjust
the dose of rituximab infusion. This indicator helps to avoid over-immunosup-
pression and to optimize the duration of B-lymphocyte (CD19+) depletion.
Case Summaries: Patient 1: A 10-year-old boy had been diagnosed with steroid-
dependent nephrotic syndrome since 2 years of age and was resistant to cyclo-
phosphamide therapy. His nephrotic syndrome remitted with cyclosporin A but
with frequent relapses.Renalbiopsyconfirmedfocalsegmentalglomerulosclero-
sis. He had serious complications of steroid and became tacrolimus dependent.
Two doses of rituximab infusion (375 mg/m2) were given weekly. Depletion of
B-lymphocyte (CD19+) was achieved after the 2nd dose of rituximab. His protein-
uria improvedandhis steroidwasweanedoff 5monthsafter rituximab (Figure 1).
Patient 2: A 16-year-old girl was diagnosed with systemic lupus erythematosus
at 6 years of age. She had class III lupus nephritis diagnosed at 11 years old and
was given a course of oral cyclophosphamide, followed by maintenance
azathioprine and prednisolone. Mycophenolate mofetil and tacrolimus were
added for recurrent relapses and uncontrolled disease. Two doses of rituximab
infusion 500 mg (375 mg/m2) were given weekly. She achieved better disease
control with B-lymphocyte (CD19+) depletion which lasted for 4 months. Pred-
nisolone was tapered to 7 mg daily. She experienced another relapse with
nephrotic range proteinuria 9 months later. Another two doses of rituximab
were given with good response. B-lymphocyte (CD19+) depletion lasted for
another 10 weeks (Figure 2) and her prednisolone was reduced to 5 mg daily.Figure 1. CD19+ count and urine protein / creatinine ratio after rituximab
infusion of patient 1.Figure 2: CD19+ count and urine protein / creatinine ratio after rituximab
infusion of patient 2.Conclusion: Two doses of rituximab can successfully deplete B-lymphocyte
(CD19+). Monitoring of B-lymphocyte (CD19+) counts helps to adjust the
dose of rituximab so as to prolong the duration of lymphocyte subset
depletion.http://dx.doi.org/10.1016/j.hkjn.2015.08.137
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“Late” is the Most Prominent Feature and Risk Factor for Patients with
Late-onset Lupus Nephritis
Na Tian, Wei Chen, Qian Zhou, Ling Yao Hong, Qi Mei Luo, Xue Qing Yu
Sun Yat-Sen University, GuangZhou, China
Objective: To distinguish the clinical and pathological characteristic of late-
onset lupus nephritis (LN) patients and their prognosis.
Methods: This is a retrospective cohort study. Patients who were diagnosed
as LN with age  14 from January 1st 1996 to December 31st 2011 were
enrolled. Baseline clinical characteristics and pathological information
were compared between late-onset group (LG) (onset age of LN  50) and
the control group (CG) (onset age of LN < 50), while the patient survival
and renal outcome (definded as serum creatinine doubled or ESRD) were fol-
lowed-up.
Results: Totally, 1264 patients were enrolled, with102 cases in LG and
1162 cases in CG. (1) The male to female ratio of LG was 2:5, doubling
to the CG (P Z 0.001). Patients in LG had more complications, higher sys-
tolic blood pressure and worse renal function (median eGFR: 59.59 vs
104.9 ml/min, P< 0.001). Patients with late-onset LN had a higher inci-
dence of AKI (27.5% vs 16.5%, P Z 0.005). No difference was shown on ac-
tivity index of SLE between the two groups. The renal pathological
comparisons indicated that chronic lesions of the LG were much more con-
spicuous than the CG, while the activity lesions of LN in two groups were
similar. (2) During the follow-up time of 55 (1, 207) months, 291 patients
reached the end-point, including 114 (13.1%) deaths, 107 (12.2%) creati-
nine doubled, and 80 (9.1%) ESRD. Kaplan-Meier curves showed that 5-
year and 10-year survival rates of LG were 68.5% and 49.1%, respectively,
much lower than that of the CG (P< 0.001). Patients in the LG had a worse
renal survival compared to CG (log rank Z 0.849, P Z 0.008). The older
onset-age was an independent risk factor for LN patients survival after
adjusted for confounders (HR Z 3.034, P Z 0.005). Increased Scr at base-
line was independently associated with renal survival while 1.1 mg/dL-
increment of Scr would lead to the hazard ratio of renal disfunction
increasing by 45% (P< 0.001).
Conclusion: The worse renal outcome of late-onset LN patients was more
likely to be associated with the decline renal function with aging than the
activity of SLE itself.http://dx.doi.org/10.1016/j.hkjn.2015.08.138
0155
Clinicopathological Characteristics and Outcomes in Male Patients with
Lupus Nephritis
Liping Xiong, Na Tian, Linyao Hong, Wang Zhang, Wei Chen, Xueqing Yu
Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen
University, Guangzhou, China
Objective: Long-term outcome of lupus nephritis (LN) in male patients is a
controversial issue. The objective is to evaluate clinicopathological charac-
teristics as well as renal and patient survival in male patients with lupus
nephritis.
Methods: All patients who fulfilled American College of Rheumatology lupus
Criteria were enrolled in the study. Clinicalpathological data of lupus
nephritis patients with different gender were retrospectively analyzed and
compared. Kaplan-Meier analysis and the Cox proportional hazards models
were used to evaluate the risk factors associated with renal and patient sur-
vival in male lupus nephritis patients.
Results: A total of 1272 lupus nephritis patients were enrolled, with a
mean age of 31.3  13.4 years. Among them, 215 were male and 1057
were female. Clinical presentation was similar except that males had a
significantly lower proportion of alopecia, arthralgia and leucocytopenia,
